首页 > 最新文献

BMC Dermatology最新文献

英文 中文
Cutaneous sarcoidosis masquerading as chronic cutaneous lupus erythematosus - case report 皮肤结节病伪装成慢性皮肤红斑狼疮1例
Q2 Medicine Pub Date : 2016-09-20 DOI: 10.1186/s12895-016-0052-3
M. Vatanchi, K. Sobhani, Valerie Fisher, J. Meffert
{"title":"Cutaneous sarcoidosis masquerading as chronic cutaneous lupus erythematosus - case report","authors":"M. Vatanchi, K. Sobhani, Valerie Fisher, J. Meffert","doi":"10.1186/s12895-016-0052-3","DOIUrl":"https://doi.org/10.1186/s12895-016-0052-3","url":null,"abstract":"","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0052-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66135590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). 胰岛素增敏剂(二甲双胍和吡格列酮)在银屑病伴代谢综合征患者中的随机安慰剂对照研究(局部治疗队列)。
Q2 Medicine Pub Date : 2016-08-17 DOI: 10.1186/s12895-016-0049-y
Surjit Singh, Anil Bhansali

Background: Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).

Methods: Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.

Results: Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values - PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values - PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value - PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue - PASI = 0.001, ESI = 0.001). Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.

Conclusion: Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.

Trial registration: CTRI Registration Number: CTRI/2011/12/002252 . Registered on 19/12/2011.

背景:代谢综合征(MS)在银屑病中的患病率增加。二甲双胍显示改善心血管危险因素,而吡格列酮显示抗增殖、抗炎和抗血管生成作用。研究目的是评价胰岛素增敏剂(二甲双胍和吡格列酮)治疗银屑病伴代谢综合征(MS)患者的疗效和安全性。方法:单中心、平行组、随机对照研究二甲双胍、吡格列酮和安慰剂对ms型银屑病患者的治疗效果。结果:吡格列酮组(p值- PASI = 0.001, ESI = 0.002, PGA = 0.008)和二甲双胍组(p值- PASI = 0.001, ESI = 0.016, PGA = 0.012)与安慰剂组相比,银屑病面积和严重程度指数(PASI)、红斑、结皮和硬结(ESI)和医师总体评估(PGA)评分均有统计学意义的改善。在二甲双胍组(p值- PASI = 0.001, ESI = 0.001)和吡格列酮组(p值- PASI = 0.001, ESI = 0.001)中PASI和ESI评分降低75%的患者百分比有统计学意义。二甲双胍组和吡格列酮组的空腹血糖(FPG)和甘油三酯水平均有显著改善。二甲双胍治疗12周后,体重、BMI、腰围、FPG、甘油三酯和总胆固醇均有显著改善,吡格列酮治疗12周后,FPG、甘油三酯水平、收缩压(SBP)、舒张压(DBP)、总胆固醇和低密度脂蛋白胆固醇水平均有改善。三组患者药物不良反应类型无差异。结论:胰岛素增敏剂可改善银屑病患者的MS参数和病情严重程度。试验注册:CTRI注册号:CTRI/2011/12/002252。于2011年12月19日注册。
{"title":"Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).","authors":"Surjit Singh,&nbsp;Anil Bhansali","doi":"10.1186/s12895-016-0049-y","DOIUrl":"https://doi.org/10.1186/s12895-016-0049-y","url":null,"abstract":"<p><strong>Background: </strong>Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).</p><p><strong>Methods: </strong>Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.</p><p><strong>Results: </strong>Statistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values - PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values - PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value - PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue - PASI = 0.001, ESI = 0.001). Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.</p><p><strong>Conclusion: </strong>Insulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.</p><p><strong>Trial registration: </strong>CTRI Registration Number: CTRI/2011/12/002252 . Registered on 19/12/2011.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2016-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0049-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34312577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 46
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. 一项多中心、随机、开放标签的试点试验,评估依那西普50 mg每周2次,随后依那西普25 mg每周2次,依那西普25 mg每周2次与阿维甲素联合,以及单独使用阿维甲素治疗中重度牛皮癣患者的疗效和安全性。
Q2 Medicine Pub Date : 2016-07-25 DOI: 10.1186/s12895-016-0048-z
Joo-Heung Lee, Jai-Il Youn, Tae-Yoon Kim, Jee-Ho Choi, Chul-Jong Park, Yong-Beom Choe, Hae-Jun Song, Nack-In Kim, Kwang-Joong Kim, Jeung-Hoon Lee, Hyun-Jeong Yoo

Background: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis.

Methods: Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24.

Results: The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients.

Conclusion: In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study.

Trial registration: This study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065 .

背景:依那西普(一种可溶性肿瘤坏死因子受体)和阿维素已被证明对治疗牛皮癣有效。阿曲维素在韩国被广泛使用。然而,依那西普联合阿维甲素在韩国银屑病患者中尚未进行评估。本研究的目的是探讨依那西普和阿维甲素联合治疗中重度斑块型银屑病的疗效和安全性。方法:60例银屑病患者随机接受依那西普50 mg,每周2次(BIW),连续12周,随后接受依那西普25 mg,每周2次(ETN-ETN);依那普25mg BIW加阿维素10mg,每日两次(BID),持续24周(ETN-ACT);或活塞素10mg BID, 24周(ACT)。主要疗效测量是第24周时银屑病面积和严重程度指数(PASI 75)改善75%的患者比例。次要终点包括第24周时PASI改善50% (PASI 50),第24周每次就诊时医师总体评估(PGA)清除/几乎清除。结果:在第24周,ETN-ETN组(分别为52.4、71.4和52.4%)和ETN-ACT组(分别为57.9、84.2和52.6%)达到PASI 75、PASI 50和PGA清除/几乎清除的患者比例高于ACT组(分别为22.2、44.4和16.7%)。所有组的不良事件发生率相似。这是一项少数患者的开放标签研究。结论:在韩国中重度斑块型银屑病患者中,依那西普单用或联用阿维甲素比阿维甲素更有效。在整个研究过程中,所有治疗方法均具有良好的耐受性。试验注册:本研究于2009年7月7日在ClinicalTrials.gov注册,注册号为NCT00936065。
{"title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.","authors":"Joo-Heung Lee,&nbsp;Jai-Il Youn,&nbsp;Tae-Yoon Kim,&nbsp;Jee-Ho Choi,&nbsp;Chul-Jong Park,&nbsp;Yong-Beom Choe,&nbsp;Hae-Jun Song,&nbsp;Nack-In Kim,&nbsp;Kwang-Joong Kim,&nbsp;Jeung-Hoon Lee,&nbsp;Hyun-Jeong Yoo","doi":"10.1186/s12895-016-0048-z","DOIUrl":"https://doi.org/10.1186/s12895-016-0048-z","url":null,"abstract":"<p><strong>Background: </strong>Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis.</p><p><strong>Methods: </strong>Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24.</p><p><strong>Results: </strong>The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients.</p><p><strong>Conclusion: </strong>In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study.</p><p><strong>Trial registration: </strong>This study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065 .</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2016-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0048-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34702111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patch testing in Iranian children with allergic contact dermatitis. 伊朗儿童过敏性接触性皮炎的斑贴试验。
Q2 Medicine Pub Date : 2016-07-12 DOI: 10.1186/s12895-016-0047-0
Hossein Mortazavi, Amirhooshang Ehsani, Seyed Sajed Sajjadi, Nessa Aghazadeh, Ebrahim Arian

Background: Allergic contact dermatitis is a common disorder in adults and children alike and appears to be on the increase. The purpose of this study was to determine the sensitization trends in Iranian children with contact dermatitis.

Methods: The result of 109 patch tests performed using the 24 allergens of the European Standard Series in patients below 18 years old from September 2007 to March 2009 were recorded and analyzed. The tests were evaluated at 48 and 72 h after performing.

Results: The study population consisted of 72 (66.1 %) females and 37 (33.9 %) males. Hands were the most commonly affected anatomic site. In the final evaluation of the tests on day three, 51 (46.8 %) individuals showed a positive reaction to at least one allergen. Females were significantly more likely to show a positive response to at least one allergen (p-value = 0.031, odds ratio: 2.46). The most common allergens were nickel sulfate, cobalt, methylisothiazolinone, and colophony with 21 (19.3 %), 11 (10.1 %), 7 (6.4 %), and 6 (5.5 %) positive reactions, respectively. Contact allergy to nickel sulfate was more common in females than males (23.6 % vs. 10.8 %). There was no statistically significant relationship between personal or family history of atopy and a positive reaction to patch testing. The clinical and practical relevance were assessed for nickel and cobalt with a clinical current relevance in 11 (52.3 %) and 4 (36.4 %), respectively.

Conclusions: Nickel sulfate, cobalt, methylisothiazolinone, and colophony are the most common allergens responsible for induction of allergic contact dermatitis in Iranian children and adolescents. Females tended to show more positive reactions to allergens.

背景:过敏性接触性皮炎是一种常见的疾病,在成人和儿童一样,似乎在增加。本研究的目的是确定伊朗接触性皮炎儿童的致敏趋势。方法:对2007年9月至2009年3月对18岁以下患者使用欧洲标准系列24种过敏原进行的109次斑贴试验结果进行记录和分析。在术后48和72小时进行评估。结果:研究人群中女性72人(66.1%),男性37人(33.9%)。手是最常受影响的解剖部位。在第三天测试的最终评估中,51人(46.8%)对至少一种过敏原表现出阳性反应。女性更有可能对至少一种过敏原表现出阳性反应(p值= 0.031,优势比:2.46)。最常见的过敏原为硫酸镍、钴、甲基异噻唑啉酮和树脂,阳性反应分别为21例(19.3%)、11例(10.1%)、7例(6.4%)和6例(5.5%)。接触性硫酸镍过敏女性比男性更常见(23.6%比10.8%)。个人或家族特应性史与贴片试验阳性反应之间没有统计学意义的关系。评估镍和钴的临床和实际相关性,其中临床当前相关性分别为11例(52.3%)和4例(36.4%)。结论:硫酸镍、钴、甲基异噻唑啉酮和松香是诱发伊朗儿童和青少年过敏性接触性皮炎最常见的过敏原。女性对过敏原的反应更积极。
{"title":"Patch testing in Iranian children with allergic contact dermatitis.","authors":"Hossein Mortazavi,&nbsp;Amirhooshang Ehsani,&nbsp;Seyed Sajed Sajjadi,&nbsp;Nessa Aghazadeh,&nbsp;Ebrahim Arian","doi":"10.1186/s12895-016-0047-0","DOIUrl":"https://doi.org/10.1186/s12895-016-0047-0","url":null,"abstract":"<p><strong>Background: </strong>Allergic contact dermatitis is a common disorder in adults and children alike and appears to be on the increase. The purpose of this study was to determine the sensitization trends in Iranian children with contact dermatitis.</p><p><strong>Methods: </strong>The result of 109 patch tests performed using the 24 allergens of the European Standard Series in patients below 18 years old from September 2007 to March 2009 were recorded and analyzed. The tests were evaluated at 48 and 72 h after performing.</p><p><strong>Results: </strong>The study population consisted of 72 (66.1 %) females and 37 (33.9 %) males. Hands were the most commonly affected anatomic site. In the final evaluation of the tests on day three, 51 (46.8 %) individuals showed a positive reaction to at least one allergen. Females were significantly more likely to show a positive response to at least one allergen (p-value = 0.031, odds ratio: 2.46). The most common allergens were nickel sulfate, cobalt, methylisothiazolinone, and colophony with 21 (19.3 %), 11 (10.1 %), 7 (6.4 %), and 6 (5.5 %) positive reactions, respectively. Contact allergy to nickel sulfate was more common in females than males (23.6 % vs. 10.8 %). There was no statistically significant relationship between personal or family history of atopy and a positive reaction to patch testing. The clinical and practical relevance were assessed for nickel and cobalt with a clinical current relevance in 11 (52.3 %) and 4 (36.4 %), respectively.</p><p><strong>Conclusions: </strong>Nickel sulfate, cobalt, methylisothiazolinone, and colophony are the most common allergens responsible for induction of allergic contact dermatitis in Iranian children and adolescents. Females tended to show more positive reactions to allergens.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2016-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0047-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34659926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice. 12- o -十四烷醇-13-醋酸酯诱导的银屑病样皮肤病变对高胆固醇血症载脂蛋白E缺乏小鼠全身炎症和动脉粥样硬化的影响
Q2 Medicine Pub Date : 2016-07-11 DOI: 10.1186/s12895-016-0046-1
Marie Madsen, Peter Riis Hansen, Lars Bo Nielsen, Karsten Hartvigsen, Anders Elm Pedersen, Jan Pravsgaard Christensen, Annemarie Aarup, Tanja Xenia Pedersen

Background: Risk of cardiovascular disease is increased in patients with psoriasis, but molecular mechanisms linking the two conditions have not been clearly established. Lack of appropriate animal models has hampered generation of new knowledge in this area of research and we therefore sought to develop an animal model with combined atherosclerosis and psoriasis-like skin inflammation.

Methods: Topical 12-O-tetradecanoylphorbol-13-acetate (TPA) was applied to the ears twice per week for 8 weeks in atherosclerosis-prone apolipoprotein E deficient (ApoE(-/-)) mice.

Results: TPA led to localized skin inflammation with increased epidermal thickness, infiltration of inflammatory-like cells and augmented tissue interleukin-17F levels. Systemic effects of the topical application of TPA were demonstrated by increased plasma concentration of serum amyloid A and splenic immune modulation, respectively. However, atherosclerotic plaque area and composition, and mRNA levels of several inflammatory genes in the aortic wall were not significantly affected by TPA-induced skin inflammation.

Conclusions: TPA-induced psoriasis-like skin inflammation in atherosclerosis-prone ApoE(-/-) mice evoked systemic immune-inflammatory effects, but did not affect atherogenesis. The results may question the role of psoriasis-induced inflammation in the pathogenesis of atherosclerosis in psoriasis patients.

背景:银屑病患者发生心血管疾病的风险增加,但两者之间的分子机制尚未明确确立。缺乏合适的动物模型阻碍了这一研究领域新知识的产生,因此我们寻求开发一种动脉粥样硬化和牛皮癣样皮肤炎症合并的动物模型。方法:对动脉粥样硬化易发载脂蛋白E缺乏(ApoE(-/-))小鼠,每周2次外用12- o -十四烷醇-13-醋酸酯(TPA)。结果:TPA导致局部皮肤炎症,表皮厚度增加,炎症样细胞浸润,组织白细胞介素- 17f水平升高。局部应用TPA的全身效应分别通过增加血清淀粉样蛋白A的血浆浓度和脾免疫调节来证明。然而,tpa诱导的皮肤炎症对动脉粥样硬化斑块的面积和组成以及主动脉壁几种炎症基因的mRNA水平没有显著影响。结论:tpa诱导的易发生动脉粥样硬化的ApoE(-/-)小鼠牛皮癣样皮肤炎症引起全身免疫炎症作用,但不影响动脉粥样硬化。结果可能会质疑银屑病诱导炎症在银屑病患者动脉粥样硬化发病机制中的作用。
{"title":"Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice.","authors":"Marie Madsen,&nbsp;Peter Riis Hansen,&nbsp;Lars Bo Nielsen,&nbsp;Karsten Hartvigsen,&nbsp;Anders Elm Pedersen,&nbsp;Jan Pravsgaard Christensen,&nbsp;Annemarie Aarup,&nbsp;Tanja Xenia Pedersen","doi":"10.1186/s12895-016-0046-1","DOIUrl":"https://doi.org/10.1186/s12895-016-0046-1","url":null,"abstract":"<p><strong>Background: </strong>Risk of cardiovascular disease is increased in patients with psoriasis, but molecular mechanisms linking the two conditions have not been clearly established. Lack of appropriate animal models has hampered generation of new knowledge in this area of research and we therefore sought to develop an animal model with combined atherosclerosis and psoriasis-like skin inflammation.</p><p><strong>Methods: </strong>Topical 12-O-tetradecanoylphorbol-13-acetate (TPA) was applied to the ears twice per week for 8 weeks in atherosclerosis-prone apolipoprotein E deficient (ApoE(-/-)) mice.</p><p><strong>Results: </strong>TPA led to localized skin inflammation with increased epidermal thickness, infiltration of inflammatory-like cells and augmented tissue interleukin-17F levels. Systemic effects of the topical application of TPA were demonstrated by increased plasma concentration of serum amyloid A and splenic immune modulation, respectively. However, atherosclerotic plaque area and composition, and mRNA levels of several inflammatory genes in the aortic wall were not significantly affected by TPA-induced skin inflammation.</p><p><strong>Conclusions: </strong>TPA-induced psoriasis-like skin inflammation in atherosclerosis-prone ApoE(-/-) mice evoked systemic immune-inflammatory effects, but did not affect atherogenesis. The results may question the role of psoriasis-induced inflammation in the pathogenesis of atherosclerosis in psoriasis patients.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2016-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0046-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34657939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Enzymatic debridement for the treatment of severely burned upper extremities - early single center experiences. 酶清创治疗严重烧伤上肢-早期单中心经验。
Q2 Medicine Pub Date : 2016-06-24 DOI: 10.1186/s12895-016-0045-2
Tomke Cordts, Johannes Horter, Julian Vogelpohl, Thomas Kremer, Ulrich Kneser, Jochen-Frederick Hernekamp

Background: Severe burns of hands and arms are complex and challenging injuries. The Standard of care (SOC) - necrosectomy with skin grafting - is often associated with poor functional or aesthetic outcome. Enzymatic debridement (ED) is considered one promising alternative but, until recently, results proved to be highly variable.

Methods: Between 04/2014 and 04/2015, 16 patients with deep partial- to full-thickness burns of the upper extremities underwent enzymatic debridement (ED) in our Burn Center and were evaluated for extent of additional surgery, wound healing, pain management and functional parameters.

Results: Following ED, no further surgical intervention was required in 53.8 % of the study population. In patients who required surgical treatment, the the skin-grafted area could be reduced by 37.0 % when compared to initial assessment. Time from injury to ED was 24.4 h and patients were able to start physical therapy after 2.0 days but suffered from prolonged wound closure (28.0 days). Regionally administered anesthesia proved to be superior to pain medication alone as pain levels and consumed morphine-equivalent were lower. Post-demission follow-up showed good functional results and pain levels with low scores in two self-report questionnaires (DASH, PRWE-G) but 3 patients reported increased susceptibility to shear stress. Based on these early experiences, we developed a 3-step algorithm for consecutive patients allowing appropriate and individualized treatment selection.

Conclusions: We see a potential benefit for ED in the treatment of severely burned hands and forearms but further investigations and proper prospective, randomized controlled trials are needed to statistically support any outlined assumptions.

背景:手部和手臂严重烧伤是一种复杂且具有挑战性的损伤。标准护理(SOC) -坏死性切开术与皮肤移植-往往与不良的功能或美观的结果有关。酶清创(ED)被认为是一种有希望的替代方法,但直到最近,结果被证明是高度可变的。方法:2014年4月至2015年4月,16例上肢深度部分至全层烧伤患者在我们的烧伤中心接受了酶清创(ED)治疗,并评估了额外手术的程度、伤口愈合、疼痛管理和功能参数。结果:在ED后,53.8%的研究人群不需要进一步的手术干预。在需要手术治疗的患者中,与初始评估相比,植皮面积可减少37.0%。从损伤到ED的时间为24.4 h,患者在2.0天后可以开始物理治疗,但伤口愈合时间较长(28.0天)。局部麻醉被证明优于单独止痛药,因为疼痛水平和消耗的吗啡当量较低。出院后随访显示功能恢复良好,两项自我报告问卷(DASH, PRWE-G)得分较低,疼痛水平较低,但有3例患者报告剪应力易感性增加。基于这些早期的经验,我们为连续患者开发了一个三步算法,允许适当和个性化的治疗选择。结论:我们看到ED治疗手部和前臂严重烧伤的潜在益处,但需要进一步的调查和适当的前瞻性随机对照试验来统计支持任何概述的假设。
{"title":"Enzymatic debridement for the treatment of severely burned upper extremities - early single center experiences.","authors":"Tomke Cordts,&nbsp;Johannes Horter,&nbsp;Julian Vogelpohl,&nbsp;Thomas Kremer,&nbsp;Ulrich Kneser,&nbsp;Jochen-Frederick Hernekamp","doi":"10.1186/s12895-016-0045-2","DOIUrl":"https://doi.org/10.1186/s12895-016-0045-2","url":null,"abstract":"<p><strong>Background: </strong>Severe burns of hands and arms are complex and challenging injuries. The Standard of care (SOC) - necrosectomy with skin grafting - is often associated with poor functional or aesthetic outcome. Enzymatic debridement (ED) is considered one promising alternative but, until recently, results proved to be highly variable.</p><p><strong>Methods: </strong>Between 04/2014 and 04/2015, 16 patients with deep partial- to full-thickness burns of the upper extremities underwent enzymatic debridement (ED) in our Burn Center and were evaluated for extent of additional surgery, wound healing, pain management and functional parameters.</p><p><strong>Results: </strong>Following ED, no further surgical intervention was required in 53.8 % of the study population. In patients who required surgical treatment, the the skin-grafted area could be reduced by 37.0 % when compared to initial assessment. Time from injury to ED was 24.4 h and patients were able to start physical therapy after 2.0 days but suffered from prolonged wound closure (28.0 days). Regionally administered anesthesia proved to be superior to pain medication alone as pain levels and consumed morphine-equivalent were lower. Post-demission follow-up showed good functional results and pain levels with low scores in two self-report questionnaires (DASH, PRWE-G) but 3 patients reported increased susceptibility to shear stress. Based on these early experiences, we developed a 3-step algorithm for consecutive patients allowing appropriate and individualized treatment selection.</p><p><strong>Conclusions: </strong>We see a potential benefit for ED in the treatment of severely burned hands and forearms but further investigations and proper prospective, randomized controlled trials are needed to statistically support any outlined assumptions.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2016-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0045-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34609714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 58
The first Danish family reported with an AQP5 mutation presenting diffuse non-epidermolytic palmoplantar keratoderma of Bothnian type, hyperhidrosis and frequent Corynebacterium infections: a case report. 第一个丹麦家庭报告了AQP5突变,表现为弥漫性非表皮松解性掌跖角化病,多汗和频繁的杆状杆菌感染:1例报告。
Q2 Medicine Pub Date : 2016-06-03 DOI: 10.1186/s12895-016-0044-3
Anne Bruun Krøigård, Liv Eline Hetland, Ole Clemmensen, Diana C Blaydon, Jens Michael Hertz, Anette Bygum

Background: An autosomal dominant form of diffuse non-epidermolytic palmoplantar keratoderma, palmoplantar keratoderma of Bothnian type, is caused by mutations in the AQP5 gene encoding the cell-membrane water channel protein aquaporin 5 leading to defective epidermal-water-barrier function in the epidermis of the palms and soles.

Case presentation: We report the first Danish family diagnosed with diffuse non-epidermolytic palmoplantar keratoderma of Bothnian type in which fourteen individuals are potentially affected. The proband, a 36-year-old male had since childhood been affected by pronounced hyperhidrosis of the palms and soles along with palmoplantar keratoderma. He reported a very distinctive feature of the disorder, aquagenic wrinkling, as he developed pronounced maceration of the skin with translucent white papules and a spongy appearance following exposure to water. The patient presented recurrent fungal infections, a wellknown feature of the condition, but also periodic worsening with pitted keratolysis and malodour due to bacterial infections.

Conclusions: Palmoplantar keratoderma of Bothnian type, which may be associated with hyperhidrosis, is frequently complicated by fungal infections and may be complicated by Corynebacterium infections.

背景:弥漫性非表皮松解性掌跖角化病Bothnian型掌跖角化病是一种常染色体显性遗传病,是由编码细胞膜水通道蛋白水通道蛋白5的AQP5基因突变引起的,导致掌和足底表皮的表皮水屏障功能缺陷。病例介绍:我们报告了第一个丹麦家庭被诊断为弥漫性非表皮松解性掌跖角化皮病的博茨瓦纳型,其中14个人是潜在的影响。先证者为36岁男性,自幼患有明显的手掌和脚底多汗症,并伴有掌足底角化病。他报告了这种疾病的一个非常明显的特征,水源性皱纹,因为他的皮肤出现了明显的浸渍,带有半透明的白色丘疹和海绵状外观,暴露在水中。患者表现为复发性真菌感染,这是该疾病的一个众所周知的特征,但也因细菌感染而周期性恶化,出现角化凹陷和恶臭。结论:Bothnian型掌跖角化病可能伴有多汗症,常并发真菌感染,也可能并发杆状杆菌感染。
{"title":"The first Danish family reported with an AQP5 mutation presenting diffuse non-epidermolytic palmoplantar keratoderma of Bothnian type, hyperhidrosis and frequent Corynebacterium infections: a case report.","authors":"Anne Bruun Krøigård,&nbsp;Liv Eline Hetland,&nbsp;Ole Clemmensen,&nbsp;Diana C Blaydon,&nbsp;Jens Michael Hertz,&nbsp;Anette Bygum","doi":"10.1186/s12895-016-0044-3","DOIUrl":"https://doi.org/10.1186/s12895-016-0044-3","url":null,"abstract":"<p><strong>Background: </strong>An autosomal dominant form of diffuse non-epidermolytic palmoplantar keratoderma, palmoplantar keratoderma of Bothnian type, is caused by mutations in the AQP5 gene encoding the cell-membrane water channel protein aquaporin 5 leading to defective epidermal-water-barrier function in the epidermis of the palms and soles.</p><p><strong>Case presentation: </strong>We report the first Danish family diagnosed with diffuse non-epidermolytic palmoplantar keratoderma of Bothnian type in which fourteen individuals are potentially affected. The proband, a 36-year-old male had since childhood been affected by pronounced hyperhidrosis of the palms and soles along with palmoplantar keratoderma. He reported a very distinctive feature of the disorder, aquagenic wrinkling, as he developed pronounced maceration of the skin with translucent white papules and a spongy appearance following exposure to water. The patient presented recurrent fungal infections, a wellknown feature of the condition, but also periodic worsening with pitted keratolysis and malodour due to bacterial infections.</p><p><strong>Conclusions: </strong>Palmoplantar keratoderma of Bothnian type, which may be associated with hyperhidrosis, is frequently complicated by fungal infections and may be complicated by Corynebacterium infections.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2016-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0044-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34604979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. 热介导的体外和体外人皮肤损伤角质形成细胞凋亡的减少。
Q2 Medicine Pub Date : 2016-05-26 DOI: 10.1186/s12895-016-0043-4
Leslie Calapre, Elin S Gray, Sandrine Kurdykowski, Anthony David, Prue Hart, Pascal Descargues, Mel Ziman

Background: UV radiation induces significant DNA damage in keratinocytes and is a known risk factor for skin carcinogenesis. However, it has been reported previously that repeated and simultaneous exposure to UV and heat stress increases the rate of cutaneous tumour formation in mice. Since constant exposure to high temperatures and UV are often experienced in the environment, the effects of exposure to UV and heat needs to be clearly addressed in human epidermal cells.

Methods: In this study, we determined the effects of repeated UVB exposure 1 kJ/m(2) followed by heat (39 °C) to human keratinocytes. Normal human ex vivo skin models and primary keratinocytes (NHEK) were exposed once a day to UVB and/or heat stress for four consecutive days. Cells were then assessed for changes in proliferation, apoptosis and gene expression at 2 days post-exposure, to determine the cumulative and persistent effects of UV and/or heat in skin keratinocytes.

Results: Using ex vivo skin models and primary keratinocytes in vitro, we showed that UVB plus heat treated keratinocytes exhibit persistent DNA damage, as observed with UVB alone. However, we found that apoptosis was significantly reduced in UVB plus heat treated samples. Immunohistochemical and whole genome transcription analysis showed that multiple UVB plus heat exposures induced inactivation of the p53-mediated stress response. Furthermore, we demonstrated that repeated exposure to UV plus heat induced SIRT1 expression and a decrease in acetylated p53 in keratinocytes, which is consistent with the significant downregulation of p53-regulated pro-apoptotic and DNA damage repair genes in these cells.

Conclusion: Our results suggest that UVB-induced p53-mediated cell cycle arrest and apoptosis are reduced in the presence of heat stress, leading to increased survival of DNA damaged cells. Thus, exposure to UVB and heat stress may act synergistically to allow survival of damaged cells, which could have implications for initiation skin carcinogenesis.

背景:紫外线辐射在角质形成细胞中诱导显著的DNA损伤,是已知的皮肤癌发生的危险因素。然而,先前有报道称,重复和同时暴露于紫外线和热应激会增加小鼠皮肤肿瘤的形成率。由于在环境中经常经历持续暴露于高温和紫外线,因此需要明确解决暴露于紫外线和热量对人体表皮细胞的影响。方法:在本研究中,我们测定了重复暴露于1 kJ/m(2)的UVB后加热(39°C)对人角质形成细胞的影响。正常人离体皮肤模型和原代角质形成细胞(NHEK)每天暴露一次UVB和/或热应激,连续4天。然后在暴露后2天评估细胞增殖、凋亡和基因表达的变化,以确定紫外线和/或热量对皮肤角质形成细胞的累积和持续影响。结果:使用离体皮肤模型和体外原代角质形成细胞,我们发现UVB加热处理的角质形成细胞表现出持续的DNA损伤,与单独使用UVB观察到的结果相同。然而,我们发现在UVB加热处理的样品中,细胞凋亡明显减少。免疫组织化学和全基因组转录分析表明,多次UVB加热暴露诱导p53介导的应激反应失活。此外,我们证明了反复暴露于紫外线加热诱导角化细胞中SIRT1表达和乙酰化p53减少,这与这些细胞中p53调控的促凋亡和DNA损伤修复基因的显著下调一致。结论:uvb诱导的p53介导的细胞周期阻滞和凋亡在热应激下减少,导致DNA损伤细胞的存活增加。因此,暴露于UVB和热应激可能协同作用,使受损细胞存活,这可能对皮肤癌的发生有影响。
{"title":"Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo.","authors":"Leslie Calapre,&nbsp;Elin S Gray,&nbsp;Sandrine Kurdykowski,&nbsp;Anthony David,&nbsp;Prue Hart,&nbsp;Pascal Descargues,&nbsp;Mel Ziman","doi":"10.1186/s12895-016-0043-4","DOIUrl":"https://doi.org/10.1186/s12895-016-0043-4","url":null,"abstract":"<p><strong>Background: </strong>UV radiation induces significant DNA damage in keratinocytes and is a known risk factor for skin carcinogenesis. However, it has been reported previously that repeated and simultaneous exposure to UV and heat stress increases the rate of cutaneous tumour formation in mice. Since constant exposure to high temperatures and UV are often experienced in the environment, the effects of exposure to UV and heat needs to be clearly addressed in human epidermal cells.</p><p><strong>Methods: </strong>In this study, we determined the effects of repeated UVB exposure 1 kJ/m(2) followed by heat (39 °C) to human keratinocytes. Normal human ex vivo skin models and primary keratinocytes (NHEK) were exposed once a day to UVB and/or heat stress for four consecutive days. Cells were then assessed for changes in proliferation, apoptosis and gene expression at 2 days post-exposure, to determine the cumulative and persistent effects of UV and/or heat in skin keratinocytes.</p><p><strong>Results: </strong>Using ex vivo skin models and primary keratinocytes in vitro, we showed that UVB plus heat treated keratinocytes exhibit persistent DNA damage, as observed with UVB alone. However, we found that apoptosis was significantly reduced in UVB plus heat treated samples. Immunohistochemical and whole genome transcription analysis showed that multiple UVB plus heat exposures induced inactivation of the p53-mediated stress response. Furthermore, we demonstrated that repeated exposure to UV plus heat induced SIRT1 expression and a decrease in acetylated p53 in keratinocytes, which is consistent with the significant downregulation of p53-regulated pro-apoptotic and DNA damage repair genes in these cells.</p><p><strong>Conclusion: </strong>Our results suggest that UVB-induced p53-mediated cell cycle arrest and apoptosis are reduced in the presence of heat stress, leading to increased survival of DNA damaged cells. Thus, exposure to UVB and heat stress may act synergistically to allow survival of damaged cells, which could have implications for initiation skin carcinogenesis.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2016-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0043-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34522522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C. 一例因治疗急性丙型肝炎而导致寻常型银屑病加重的红皮病病例。
Q2 Medicine Pub Date : 2016-05-26 DOI: 10.1186/s12895-016-0042-5
Eva Lemmenmeier, Barbara Gaus, Patrick Schmid, Matthias Hoffmann

Background: Skin side effects during interferon-alpha and ribavirin treatment are common, but autoimmune dermatosis triggered by interferon-alpha is rare. We describe a case of erythrodermia from exacerbated psoriasis during the treatment of acute hepatitis C with pegylated-interferon-alpha and ribavirin. The incidence of psoriasis in this circumstance is unknown and only 36 cases are described in the literature, of which only one describes an erythrodermic psoriasis flare.

Case presentation: A 50-years old healthy white man presented with the complaints of headache, muscle pain, appetite loss, yellow skin complexion and fatigue. The laboratory results showed elevated liver enzymes above 50 times the upper limit of normal and a positive antibody test and RNA for hepatitis C. A screening test 6 months earlier was negative and therefore the diagnosis of an acute hepatitis C infection was most likely. In the absence of spontaneous clearance of the virus a therapy with pegylated- interferon-α and ribavirin was initiated. After 3 weeks the patient developed red scaly papular skin lesions that evolved despite treatment with prednisone to a severe erythrodermia. A skin biopsy showed typical signs for psoriasis vulgaris. Treatment with steroids was intensified and the hepatitis C therapy stopped. The patient achieved sustained virological response for hepatitis C, but psoriatic lesions were still present 6 months after treatment.

Conclusion: Although autoimmune skin reactions under pegylated-interferon-α and ribavirin treatment are rare it is important to recognise them early to start an adequate treatment to guarantee hepatitis C treatment continuation.

背景:干扰素-α和利巴韦林治疗期间的皮肤副作用很常见,但干扰素-α引发的自身免疫性皮肤病却很少见。我们描述了一例在使用聚乙二醇化干扰素-α和利巴韦林治疗急性丙型肝炎期间因银屑病加重而出现红皮病的病例。这种情况下银屑病的发病率尚不清楚,文献中仅描述了 36 例,其中只有一例描述了红皮病型银屑病的复发:病例介绍:一名 50 岁的健康白人男子主诉头痛、肌肉疼痛、食欲不振、肤色发黄和乏力。化验结果显示肝酶升高,超过正常值上限的 50 倍,丙型肝炎抗体检测和 RNA 均呈阳性。6 个月前的筛查检测结果为阴性,因此诊断为急性丙型肝炎感染的可能性最大。在病毒没有自发清除的情况下,患者开始接受聚乙二醇干扰素α和利巴韦林治疗。3 周后,患者出现红色鳞屑性丘疹皮损,尽管使用了泼尼松治疗,但皮损仍发展为严重的红皮病。皮肤活检显示出寻常型银屑病的典型症状。医生加强了类固醇治疗,并停止了丙型肝炎治疗。患者获得了丙型肝炎持续病毒学应答,但银屑病皮损在治疗 6 个月后仍然存在:尽管在聚乙二醇干扰素-α和利巴韦林治疗中出现自身免疫性皮肤反应的情况很少见,但重要的是要及早发现这些反应,以便开始适当的治疗,保证丙型肝炎治疗的持续性。
{"title":"A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C.","authors":"Eva Lemmenmeier, Barbara Gaus, Patrick Schmid, Matthias Hoffmann","doi":"10.1186/s12895-016-0042-5","DOIUrl":"10.1186/s12895-016-0042-5","url":null,"abstract":"<p><strong>Background: </strong>Skin side effects during interferon-alpha and ribavirin treatment are common, but autoimmune dermatosis triggered by interferon-alpha is rare. We describe a case of erythrodermia from exacerbated psoriasis during the treatment of acute hepatitis C with pegylated-interferon-alpha and ribavirin. The incidence of psoriasis in this circumstance is unknown and only 36 cases are described in the literature, of which only one describes an erythrodermic psoriasis flare.</p><p><strong>Case presentation: </strong>A 50-years old healthy white man presented with the complaints of headache, muscle pain, appetite loss, yellow skin complexion and fatigue. The laboratory results showed elevated liver enzymes above 50 times the upper limit of normal and a positive antibody test and RNA for hepatitis C. A screening test 6 months earlier was negative and therefore the diagnosis of an acute hepatitis C infection was most likely. In the absence of spontaneous clearance of the virus a therapy with pegylated- interferon-α and ribavirin was initiated. After 3 weeks the patient developed red scaly papular skin lesions that evolved despite treatment with prednisone to a severe erythrodermia. A skin biopsy showed typical signs for psoriasis vulgaris. Treatment with steroids was intensified and the hepatitis C therapy stopped. The patient achieved sustained virological response for hepatitis C, but psoriatic lesions were still present 6 months after treatment.</p><p><strong>Conclusion: </strong>Although autoimmune skin reactions under pegylated-interferon-α and ribavirin treatment are rare it is important to recognise them early to start an adequate treatment to guarantee hepatitis C treatment continuation.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2016-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34586887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin. 1例女性乳头腺瘤患者表现为右侧乳头皮肤持续性红斑:病例报告、文献回顾、临床意义以及与评估和治疗乳房皮肤皮肤病患者的卫生保健提供者的相关性。
Q2 Medicine Pub Date : 2016-05-20 DOI: 10.1186/s12895-016-0041-6
Gina P Spohn, Shannon C Trotter, Gary Tozbikian, Stephen P Povoski

Background: Nipple adenoma is a very uncommon, benign proliferative process of lactiferous ducts of the nipple. Clinically, it often presents as a palpable nipple nodule, a visible nipple skin erosive lesion, and/or with discharge from the surface of the nipple skin, and is primarily seen in middle-aged women. Resultantly, nipple adenoma can clinically mimic the presentation of mammary Paget's disease of the nipple. The purpose of our current case report is to present a comprehensive review of the available data on nipple adenoma, as well as provide useful information to health care providers (including dermatologists, breast health specialists, and other health care providers) who evaluate patients with dermatologic conditions of the breast skin for appropriately clinically recognizing, diagnosing, and treating patients with nipple adenoma.

Case presentation: Fifty-three year old Caucasian female presented with a one year history of erythema and induration of the skin of the inferior aspect of the right nipple/areolar region. Skin punch biopsies showed subareolar duct papillomatosis. The patient elected to undergo complete surgical excision with right central breast resection. Final histopathologic evaluation confirmed nipple adenoma. The patient is doing well 31 months after her definitive surgical therapy.

Conclusions: Since nipple adenoma represents a benign proliferative process of the nipple, complete surgical excision is curative. However, the coexistence of nipple adenoma and ipsilateral or contralateral breast cancer is well reported in the literature. The potential for a direct causal link or association of nipple adenoma and breast cancer cannot be fully excluded.

背景:乳头腺瘤是一种非常罕见的乳头乳管良性增生过程。临床上常表现为可触及的乳头结节、可见的乳头皮肤糜烂病变和/或乳头皮肤表面有分泌物,主要见于中年妇女。因此,乳头腺瘤在临床上可以模拟乳腺乳头佩吉特病的表现。我们当前病例报告的目的是对乳头腺瘤的现有数据进行全面的回顾,并为卫生保健提供者(包括皮肤科医生、乳腺健康专家和其他卫生保健提供者)提供有用的信息,他们评估乳房皮肤皮肤病患者,以便在临床上适当地识别、诊断和治疗乳头腺瘤患者。病例介绍:53岁白人女性,右乳头下侧/乳晕区皮肤有一年的红斑和硬化史。皮肤穿刺活检显示乳晕下导管乳头状瘤。患者选择了完全的手术切除右中央乳房切除术。最终的组织病理学检查证实为乳头腺瘤。患者在接受最终手术治疗31个月后恢复良好。结论:由于乳头腺瘤是乳头的良性增生过程,完全手术切除是可治愈的。然而,乳头腺瘤与同侧或对侧乳腺癌共存的文献报道较多。不能完全排除乳头腺瘤与乳腺癌之间存在直接因果关系或关联的可能性。
{"title":"Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin.","authors":"Gina P Spohn,&nbsp;Shannon C Trotter,&nbsp;Gary Tozbikian,&nbsp;Stephen P Povoski","doi":"10.1186/s12895-016-0041-6","DOIUrl":"https://doi.org/10.1186/s12895-016-0041-6","url":null,"abstract":"<p><strong>Background: </strong>Nipple adenoma is a very uncommon, benign proliferative process of lactiferous ducts of the nipple. Clinically, it often presents as a palpable nipple nodule, a visible nipple skin erosive lesion, and/or with discharge from the surface of the nipple skin, and is primarily seen in middle-aged women. Resultantly, nipple adenoma can clinically mimic the presentation of mammary Paget's disease of the nipple. The purpose of our current case report is to present a comprehensive review of the available data on nipple adenoma, as well as provide useful information to health care providers (including dermatologists, breast health specialists, and other health care providers) who evaluate patients with dermatologic conditions of the breast skin for appropriately clinically recognizing, diagnosing, and treating patients with nipple adenoma.</p><p><strong>Case presentation: </strong>Fifty-three year old Caucasian female presented with a one year history of erythema and induration of the skin of the inferior aspect of the right nipple/areolar region. Skin punch biopsies showed subareolar duct papillomatosis. The patient elected to undergo complete surgical excision with right central breast resection. Final histopathologic evaluation confirmed nipple adenoma. The patient is doing well 31 months after her definitive surgical therapy.</p><p><strong>Conclusions: </strong>Since nipple adenoma represents a benign proliferative process of the nipple, complete surgical excision is curative. However, the coexistence of nipple adenoma and ipsilateral or contralateral breast cancer is well reported in the literature. The potential for a direct causal link or association of nipple adenoma and breast cancer cannot be fully excluded.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"16 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-016-0041-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34505388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1